SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

SciSparc announced that its subsidiary NeuroThera Labs has secured the publication of a U.S. patent application covering a novel combination of MDMA and N-acylethanolamines for treating PTSD, anxiety, and eating disorders. This IP milestone expands the joint portfolio with Clearmind Medicine, bringing the total number of published patent applications generated through the collaboration to thirteen globally.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.